
浏览全部资源
扫码关注微信
1.重庆医科大学药学院,重庆 400016
2.重庆医科大学附属大学城医院药学部,重庆 401331
硕士研究生。研究方向:临床药学。E-mail:2022120896@stu.cqmu.edu.cn
主任药师,硕士生导师,硕士。研究方向:药物新剂型、医院药学。E-mail:zhaoyuu@hotmail.com
收稿日期:2024-11-06,
修回日期:2025-03-20,
录用日期:2025-03-25,
纸质出版日期:2025-04-30
移动端阅览
郭艺楠,俞秀恒,谢雨晴,等.基于多准则决策分析的县域医共体药品目录遴选体系构建与实证 [J].中国药房,2025,36(08):914-919.
GUO Yinan,YU Xiuheng,XIE Yuqing,et al.Construction and empirical study of selection system for drug directory of county-level medical community based on multi-criteria decision analysis[J].ZHONGGUO YAOFANG,2025,36(08):914-919.
郭艺楠,俞秀恒,谢雨晴,等.基于多准则决策分析的县域医共体药品目录遴选体系构建与实证 [J].中国药房,2025,36(08):914-919. DOI: 10.6039/j.issn.1001-0408.2025.08.04.
GUO Yinan,YU Xiuheng,XIE Yuqing,et al.Construction and empirical study of selection system for drug directory of county-level medical community based on multi-criteria decision analysis[J].ZHONGGUO YAOFANG,2025,36(08):914-919. DOI: 10.6039/j.issn.1001-0408.2025.08.04.
目的
2
探索构建基于多准则决策分析的县域医共体药品目录遴选体系,为医共体药品目录的遴选提供决策依据。
方法
2
以重庆市某县域医共体为例,采用德尔菲法和层次分析法构建县域医共体药品目录遴选体系;按照所构建的指标体系对待遴选药品进行量化评分,再依据药品综合评分遴选药品目录;在该目录实施1年后通过问卷调查评估目录的实施效果。
结果
2
两轮德尔菲法专家咨询的专家权威系数均大于0.8,Kendall’s
W
分别为0.213和0.196(
P
均小于0.001)。最终确定的药品目录遴选体系包括安全性、有效性、经济性、可及性、创新性5个评价维度,共8个评价指标。按上述方法遴选的药品目录中,集采药品、医保药品、基本药物数目占比均较遴选前有所升高;化学药品的综合评分为50.25~96.31分,70~100分的药品占比由遴选前的78.06%上升为85.82%,其中抗虫药的综合评分最高,消化道及代谢类药数量最多;遴选后药品目录中药品的各指标评分和综合评分均较遴选前显著升高(
P
<0.05)。
结论
2
本研究构建的县域医共体药品目录遴选体系科学客观、可操作性强,有利于促进医共体药品的规范化统一管理。
OBJECTIVE
2
To explore the construction of selection system for drug directory of the county-level medical community based on multi-criteria decision analysis, and provide decision-making basis for the selection of drug directory of medical community.
METHODS
2
Taking county-level medical community in Chongqing as an example,Delphi method and analytic hierarchy process were employed to construct the selection system for drug directory of the county-level medical community. Selected drugs were quantitatively scored based on the constructed index system, and the drug directory was selected according to the drug’s comprehensive score. The implementation effect of the directory was then evaluated through questionnaire surveys one year after the implementation of the directory.
RESULTS
2
The expert authority coefficients of the two rounds of consultation were>0.8, with Kendall’s
W
values of 0.213 and 0.196, respectively (
P
<0.001). Finally, the selection system for drug directory of the medical community was determined to include five evaluation dimensions: safety, effectiveness, economy, accessibility, and innovation, along with eight evaluation
indicators. In the drug directory selected according to the above method, the proportions of centrally procured drugs, medical insurance drugs, and essential drugs had all increased compared to before the selection; the comprehensive scores of chemical drugs ranged from 50.25 to 96.31 scores, and the proportion of drugs scoring between 70 and 100 scores had increased from 78.06% before selection to 85.82%. Among them, antiparasitic drugs had the highest comprehensive scores, while drugs for the digestive tract and metabolism were the most numerous. The evaluation scores of each indicator and the comprehensive scores of drugs in the drug directory after the selection process increased significantly than before selection (
P
<0.05).
CONCLUSIONS
2
The selection system for drug directory of the county-level medical community constructed in this study is scientific, objective and operable. This process facilitates the promotion of standardized and unified management of drugs in the medical community.
崔兆涵 , 王虎峰 , 张子楠 . 多重制度逻辑视角下紧密型县域医共体的治理机制与组织协同:理论机理与实证检验 [J ] . 中国卫生政策研究 , 2025 , 18 ( 1 ): 2 - 9 .
国家卫生健康委员会 . 关于加快药学服务高质量发展的意见 [EB/OL ] .( 2018-11-21 )[ 2024-02-16 ] . https://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5436829.htm https://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5436829.htm .
李宵 , 任炳楠 , 赵越 , 等 . 数字化药品遴选模式实现医疗机构药品供应目录优化的探索与实践 [J ] . 中国药学杂志 , 2021 , 56 ( 24 ): 2022 - 2028 .
薛朝军 , 任炳楠 , 郭彩会 , 等 . 基于EVIDEM理念的医疗机构药品遴选多准则循证决策框架探究 [J ] . 中国医院药学杂志 , 2021 , 41 ( 3 ): 303 - 308 .
HSU J C , LIN J Y , LIN P C , et al . Comprehensive value assessment of drugs using a multi-criteria decision analysis:an example of targeted therapies for metastatic colorectal cancer treatment [J ] . PLoS One , 2019 , 14 ( 12 ): e0225938 .
THOKALA P , DEVLIN N , MARSH K , et al . Multiple criteria decision analysis for health care decision making:an introduction:report 1 of the ISPOR MCDA emerging good practices task force [J ] . Value Health , 2016 , 19 ( 1 ): 1 - 13 .
MARSH K , IJZERMAN M , THOKALA P , et al . Multiple criteria decision analysis for health care decision making:emerging good practices:report 2 of the ISPOR MCDA emerging good practices task force [J ] . Value Health , 2016 , 19 ( 2 ): 125 - 137 .
刘玉龙 , 孙燕 , 李璘 , 等 . 基层医疗机构医联体药事管理发展的现状与思考 [J ] . 安徽医药 , 2020 , 24 ( 9 ): 1884 - 1887 .
国家卫生健康委员会 . 国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知:国卫办药政发 〔2021〕 16 号[EB/OL ] .( 2021-07-28 )[ 2024-07-07 ] . http://www.nhc.gov.cn/yaozs/s2908/202107/532e20800a47415-d84adf3797b0f4869.shtml http://www.nhc.gov.cn/yaozs/s2908/202107/532e20800a47415-d84adf3797b0f4869.shtml .
赵志刚 , 董占军 , 刘建平 . 中国医疗机构药品评价与遴选快速指南 [J ] . 医药导报 , 2020 , 39 ( 11 ): 1457 - 1465 .
练璐 , 李心怡 , 邹慕蓉 , 等 . 应用改良德尔菲法构建我国家庭医生卫生服务能力指标体系 [J ] . 中国卫生资源 , 2021 , 24 ( 4 ): 448 - 452 .
WEERNINK M G M , VAANHOLT M C W , GROOTHUIS-OUDSHOORN C G M , et al . Patients’ priorities for oral anticoagulation therapy in non-valvular atrial fibrillation:a multi-criteria decision analysis [J ] . Am J Cardiovasc Drugs , 2018 , 18 ( 6 ): 493 - 502 .
董名扬 , 陈朋军 , 王舒 , 等 . 应用层次分析模型构建药品临床综合评价指标体系与量化分级 [J ] . 中国药房 , 2023 , 34 ( 11 ): 1298 - 1301 .
IMPROTA G , PERRONE A , RUSSO M A , et al . Health technology assessment(HTA)of optoelectronic biosensors for oncology by analytic hierarchy process(AHP)and Likert scale [J ] . BMC Med Res Methodol , 2019 , 19 ( 1 ): 140 .
LIANG J X , ZOU G F , GU C M , et al . Study on skin infection model of Staphylococcus aureus based on analytic hierarchy process and Delphi method [J ] . Heliyon , 2023 , 9 ( 6 ): e16327 .
林思思 , 陈丽萍 , 江绮云 , 等 . 抗肺癌药品临床综合评价指标体系的构建及实证研究 [J ] . 中国药房 , 2023 , 34 ( 11 ): 1313 - 1319 .
官海静 , 岳晓萌 , 吴久鸿 . 中国药物经济学评价指南的应用与挑战 [J ] . 中国药学杂志 , 2017 , 52 ( 13 ): 1188 - 1193 .
苏华 , 郭瑞臣 . 仿制药一致性评价的背景、实施及结局 [J ] . 中国医院药学杂志 , 2022 , 42 ( 14 ): 1502 - 1505 .
任晓悦 , 颜建周 , 丁瑞琳 , 等 . 域外典型国家药品使用环节仿制药替代促进政策的经验及启示 [J ] . 中国卫生政策研究 , 2023 , 16 ( 12 ): 49 - 55 .
0
浏览量
45
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
公网安备50010302001817